|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date18 Oct 1979 |
Phase I Study of Safety and Pharmacokinetics of Once-Daily Topical Solution in Male Subjects With Androgenetic Alopecia
This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.
Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows
Study to Evaluate the safety and efficacy of a Latanoprost/Minoxidil formulation vs. placebo for the treatment of hypotrichosis of the eyebrows.
100 Clinical Results associated with Aneira Pharma, Inc.
0 Patents (Medical) associated with Aneira Pharma, Inc.
100 Deals associated with Aneira Pharma, Inc.
100 Translational Medicine associated with Aneira Pharma, Inc.